Viking Therapeutics shareholders elect directors, ratify auditor, approve say-on-pay at 2025 annual meeting

Viking Therapeutics, Inc.

Elected Matthew W. Foehr (28.1M for, 16.2M withheld) and Charles A. Rowland, Jr. (33.0M for, 11.3M withheld) as Class I directors.
Ratified CBIZ CPAs P.C. as independent auditor for FY2025: 75.2M for, 992K against, 473K abstentions.
Advisory say-on-pay proposal approved: 29.3M for, 14.5M against, 506K abstentions, 32.4M broker non-votes.
Meeting quorum of 76.7M shares (68.3% of 112.3M outstanding shares) represented.

item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.